A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few years, though they do have some drawbacks.

Drugmakers are racing to develop the next wave of obesity and diabetes medications that they hope will be even more powerful than those currently on the market. Dani Blum, a Well reporter, explains.

A new generation of weight-loss drugs has proven remarkably effective, hugely popular, and massively lucrative in the last few years ...

The Founder built the world of Generation Loss—but what if everything they said was a lie? Game Theory dives into the twisted layers of Ranboo’s story, uncovering hidden messages, broken ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few years, though they do have some drawbacks.

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they have drawbacks.

Ranboo’s Generation Loss has gone full ARG, and it’s wild. With every new piece of content, the story gets deeper and darker. In this breakdown, I go over all the new clues, livestream details ...

Weight loss drugs like Ozempic and Wegovy are used by over 15 million adults in the U.S., or 4.5% of the population. Despite their effectiveness, they have drawbacks. Their effect may not last after ...

A rare type of cancer is growing among millennials and members of Generation X, new research shows.

Results for weight-loss drug targeting amylin find similar efficacy across different doses and high rates of side effects, raising questions about which dose Novo will pursue.

Gen-Z is redefining the workplace, demanding purpose, prioritizing mental health, expecting constant communication and pushing for transparency in leadership.

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early next year. The Danish pharma and obesity heavyweight is moving forward ...